Interestingly, our observations, together with other novel findings in prostate cancer [5,6,7,8,9,10,11,12,13,14] and other recent observations in colorectal [18], pancreatic [21], and breast cancers [22], indicate that PP2A inhibition is a common alteration found in different solid tumors and further support the potential therapeutic benefits that would be derived from the inclusion of PP2A-activating drugs in anticancer protocols. This evidence concerns the gene PTPA and prostate cancer.